Headline: Odyssey Reports Narrower Q1 Net Loss, Advances Clinical Pipeline

Odyssey (ODSY) announced a reduced net loss for the first quarter ended March 31, 2026, alongside key updates on its clinical development pipeline. The biotech firm reported a net loss of $15.2 million, or $0.35 per share, a significant improvement from the $22.8 million net loss, or $0.52 per share, recorded in the same period last year. The company highlighted progress for its lead oncology candidate, ODS-101, which remains on track to deliver Phase 2 data by late 2026. Additionally, Odyssey initiated a Phase 1 clinical trial for ODS-202, targeting autoimmune disorders, in April 2026, with initial data anticipated in early 2027. Management reiterated its focus on advancing its promising drug candidates. The improved Q1 financial performance reflects strategic cost management and continued investment in high-potential therapeutic areas.